Live news related to GENSIGHT BIOLOGICS stock (FR0013183985): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on GENSIGHT BIOLOGICS mainly cover M&A activity, analyst notes et earnings publications. The stock trades at €0,08 on Euronext Paris, up 3,36% at the last update. This page lists the articles published on GENSIGHT BIOLOGICS stock to track the share price, company announcements and any item likely to influence market perception.
GenSight Biologics reported cash and cash equivalents of €0.7 million as of September 30, 2026, compared to €1.7 million as of June 30, 2026. Paid com…
GenSight Biologics and the National Hospital of 15-20 announced on October 8, 2026 the publication, in The New England Journal of Medicine, of the res…
On October 8, 2026, the biotech company specializing in gene therapy for retinal diseases announced that two of its existing shareholders, Heights Cap…
For the first time since 2022, GenSight Biologics has treated patients with its GS010/LUMEVOQ gene therapy under paid exceptional access programs, gen…
GenSight Biologics reported a critical 47% decrease in cash reserves over three months, falling to €1.7M as of June 30, 2026, from €3.2M at the end of…
The French National Agency for the Safety of Medicines and Health Products has granted a compassionate access for GS010/LUMEVOQ, GenSight Biologics' g…
